Article Figures & Data
Figures
- Figure 1.
Vasospasm-Related Morbidity/All-Cause Mortality Within 6 Weeks
Reproduced with permission from RL Macdonald, MD, PhD.
- Figure 2.
Individual Components of the Composite Endpoint.
Reproduced with permission from RL Macdonald, MD, PhD.
Tools
No Significant Improvement in Vasospasm-Related Morbidity or All-Cause Mortality with Clazosentan after aSAH
Permalink:
